Related Experiment Video
Updated: Jun 3, 2025
A Quantitative Glycomics and Proteomics Combined Purification Strategy
Published on: March 8, 2016
Bio-affinity ultrafiltration combined with UPLC Q-Exactive Plus Orbitrap HRMS to screen potential COX-2 and 5-LOX
Yan Du1, Yu-Lang Chen2, Ying Zhang2
1Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China; State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, 210093, China.
Ethnopharmacological Relevance:
Mulberry (Morus alba L.) leaf is a well-known herbal medicine in China for thousands of years. Mulberry leaf can regulate arachidonic acid (ARA) metabolism disorder in obesity and type 2 diabetes mellitus. However, the active ingredients involved in this process are still unclear.
Aim Of Study:
To explore the potential active ingredients in mulberry leaf against ARA metabolism disorder.
Materials And Methods:
In this research, an efficient method combining affinity ultrafiltration, molecular docking, and network pharmacology was developed and applied to explore cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) inhibitors from mulberry leaf.
Results:
A total 17 potential inhibitors were screened by affinity ultrafiltration assay and identified by high resolution mass spectrometry. In addition, 8 bioactive ingredients were obtained after re-evaluated by molecular docking and network pharmacology, and their inhibitory activities on COX-2 and 5-LOX were confirmed by in vitro inhibitory assays. The results of cell experiments showed that the expressions of COX-2 and 5-LOX were significantly suppressed by neochlorogenic acid, rutin, isoquercetin, and (-)-syringaresinol-4-O-glucoside.
Conclusion:
Neochlorogenic acid, rutin, isoquercetin, and (-)-syringaresinol-4-O-glucoside may be the potential material basis of mulberry leaf in the regulation of ARA metabolism of obesity and type 2 diabetes mellitus.
